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ABSTRACT  
CAPOS (Cerebellar ataxia, Areflexia, Pes cavus, Optic atrophy and Sensorineural hearing 
impairment), is a rare clinically distinct syndrome caused by a single dominant missense 
mutation, c.2452G>A, p.Glu818Lys, in ATP1A3, encoding the neuron-specific alpha subunit 
of the Na+/K+-ATPase α3. Allelic mutations cause the neurological diseases Rapid Dystonia 
Parkinsonism (RDP) and Alternating Hemiplegia of Childhood (AHC), disorders which do 
not encompass hearing or visual impairment. 
 
We present detailed clinical phenotypic information in 18 genetically-confirmed patients 
from 11 families (10 previously unreported) from Denmark, Sweden, UK and Germany 
indicating a specific type of hearing impairment - auditory neuropathy (AN). All patients 
were clinically suspected of CAPOS and had hearing problems. In this retrospective analysis 
of audiological data, we show for the first time that cochlear outer hair cell activity was 
preserved as shown by the presence of otoacoustic emissions and cochlear microphonic 
potentials, but the auditory brainstem responses were grossly abnormal, likely reflecting 
neural dyssynchrony. Poor speech perception was observed, especially in noise, which was 
beyond the hearing level obtained in the pure tone audiograms in several of the patients 
presented here.  
Molecular modelling and in-vitro electrophysiological studies of the specific CAPOS 
mutation were performed. Heterologous expression studies of α3 with the p.Glu818Lys 
mutation affects sodium binding to, and release from, the sodium-specific site in the pump, 
the third ion binding site. Molecular dynamics simulations confirm that the structure of the C-
terminal region is affected.  
 
In conclusion, we demonstrate for the first time evidence for auditory neuropathy in CAPOS 
syndrome, which may reflect impaired propagation of electrical impulses along the spiral 
ganglion neurons. This has implications for diagnosis and patient management. Auditory 
neuropathy is difficult to treat with conventional hearing aids, but preliminary improvement 
in speech perception in some patients are encouraging for trying cochlear implantation in  
CAPOS patients.  
 
Key words: optic atrophy, auditory neuropathy, aseptic encephalitis, ATP1A3, CAPOS 
syndrome  
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INTRODUCTION  
CAPOS syndrome (OMIM 601338) is a rare but highly distinctive cause of hearing 
impairment, first described in a mother and two children in 1996 (Nicolaides 1996); seven 
further families and isolated cases (in total 22 patients) have been described subsequently 
(Demos et al 2014; Rosewich et al 2014; Heimer et al 2015; Potic et al 2015; Maas et al 
2016). It is caused by one specific, dominant, missense mutation in the ATP1A3 gene, on 
chromosome 19q13.2 (Demos et al 2014), encoding the neuron-specific alpha subunit of the 
Na+/K+-ATPase α3, while other mutations in the same gene cause neurological syndromes 
without hearing impairment or optic atrophy, namely Rapid Dystonia and Parkinsonism 
(RDP) and Alternating Hemiplegia of Childhood (AHC) (Dard et al 2015; Sweney et al 
2015). CAPOS is thus clinically and molecularly distinct. The clinical picture is remarkable, 
characterized by sudden onset of cerebellar ataxia precipitated by a febrile illness in 
childhood. Episodes are often recurrent and they can involve extended periods of reduced 
consciousness, hypotonia, ataxia and loss of the ability to walk, which may take weeks or 
months to regain. Months or years later the patients experience progressive sensorineural 
hearing impairment, optic atrophy, loss of deep tendon reflexes, and in some subjects, pes 
cavus.  Cognition and brain imaging are usually normal (Maas et al 2016). None of the 
previous reports have characterized the audiological phenotype to be an auditory neuropathy. 
 
For all three allelic disorders, AHC, RDP and CAPOS, fever has been reported as a trigger, 
and several symptoms have been observed in all three groups, including ataxia, (asymmetric) 
dystonia, dysarthria, bradykinesia and abnormal ocular movements. For AHC, there are clear 
mutational hotspots with a majority of the patients having one of three residues affected, all 
in the transmembrane part of the protein at or close to the ion binding residues. In contrast, 
the RDP-causing mutations map more broadly onto the pump structure (Clausen et al, 2017). 
Effects on protein expression have been reported for RDP, but not AHC mutations (Heinzen 
et al, 2014).  
 
The Na,K-ATPase establishes the steep gradients of sodium and potassium across animal cell 
membranes that are important for numerous processes, not least in neurons, where the firing 
of action potentials depends directly on the flow of these ions. In grey matter, it is estimated 
that as much as 75% of the energy produced in the brain is spent by the Na,K-ATPase 
(Attwell and Laughlin, 2001). A Na,K-ATPase consists of three subunits, the catalytic α and 
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two auxiliary subunits, E and FXYD, important for stability, trafficking and kinetic 
parameters (Geering et al, 2005). The α subunit has ten transmembrane helices that transport 
three Na+ ions out of the cell and take up two K+ ions at the expense of one ATP during each 
catalytic cycle (Fig. 1).   
 
There are several isoforms of each of the subunits; there are three types of α subunit in brain 
of which α1 is broadly expressed, α2 is mostly in glia cells, and α3 is in neurons (Clausen et 
al 2017; Watts et al 1991; Schuth et al 2014). In the inner ear of rats, α3 was detected in the 
spiral ganglion neurons (SGNs) on hair cells, while α1 was detected in the hair cells 
themselves. (Schuth et al. 2014).  
 
In the majority of cases sensorineural  hearing impairment is caused by defects of auditory 
transduction (conversion of sound energy into electrical activity) and active amplification of 
cochlear vibrations by the electromotile outer hair cells (OHCs). Cochlear transduction and 
amplification can be directly reported by measuring sound emissions from the ear 
(otoacoustic emissions (Kemp 1978) or cochlear microphonics (the receptor potential 
generated by OHC).  OAEs are absent when cochlear transduction and amplification fail, 
which makes them a useful screen for the majority of cases of congenital hearing impairment. 
In contrast, far less is known about hearing disorders affecting the auditory pathway beyond 
the OHCs, for example those affecting only inner hair cell (IHC) synapses, synaptic 
transmission to afferent spiral ganglion neurons (SGNs) or conduction of information by the 
auditory nerve to higher auditory centers (Rance and Starr 2015;Moser and Starr 2016). This 
type of hearing impairment is termed auditory neuropathy (AN) or auditory synaptopathy if 
synaptic sound encoding is affected.  It is characterized by normal OHC amplification and the  
presence of OAEs and/or cochlear microphonics, but abnormal auditory nerve function, as 
measured by auditory brain stem responses (ABRs) and/or compound action potential by 
electrocochleography (CAP) (Rance and Starr 2015, Santarelli et al, 2015). ABRs require the 
synchronized activation of afferent SGNs by glutamate release at IHC ribbon synapses and 
intact propagation of spikes along the auditory pathway (Moser and Starr, 2016). Precise 
timing of neural activity is an important factor on which speech intelligibility and binaural 
hearing depend (Giraudet and Avan 2012). 
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Auditory neuropathy may be an isolated feature (non-syndromic) in some patients or part of a 
more widespread neuropathy or part of a syndrome disorder in others (Starr et al 1996). The 
distinction between AN and sensory (or cochlear) hearing impairment is critically important 
for diagnosis, prognosis and rehabilitation and there is growing evidence that AN underlies 
hearing dysfunction associated with several genetic and non-genetic diseases.  
 
The combination of optic atrophy and ‘sensorineural’ hearing loss, coupled with known 
selective expression of ATP1A3 in the spiral ganglion neurons of the inner ear (McGuirt and 
Schulte 1994; Watts et al 1991; Schuth et al 2014), indicate that the hearing loss in patients 
might not be due to hair cell dysfunction but to an auditory neuropathy instead. We describe 
18 cases of CAPOS syndrome highlighting its unique clinical presentation, and provide 
evidence of an auditory neuropathy which has important implications for patient 
management. We model the specific mutation, p.Glu818Lys, in ATP1A3 which causes 
CAPOS syndrome demonstrating effects which are different to mutations associated with 
RDP and AHC to try and better understand the reasons for its unique clinical presentation. 
 
 
RESULTS 
 
Clinical details of 18 patients with CAPOS syndrome are summarized in Tables 1 and 2 and 
in Supplementary material. Pedigrees of four familial cases and representative audiograms 
are shown in figures 2 and 3. All families showed the same recurrent heterozygous mutation 
in exon 18: c.2452G>A; p.Glu818Lys (supplementary Fig. S1).  
 
Clinical histories are remarkably similar, and resemble earlier reports of CAPOS syndrome 
with episodes of reduced consciousness and ataxia, triggered by a febrile illness beginning 
suddenly in early childhood. Episodes were reminiscent of encephalitis and improved slowly 
over weeks or months with or without noticeable residual neurological deficit initially. 
Sometimes, definite but different pathogens were isolated and in case 9 three different 
pathogens were associated with three different episodes (raised mycoplasma titers, HPV6 
infection and streptococcal throat infection). Episodes were often recurrent, and most 
episodes ceased in childhood but two patients experienced their last episode at or beyond 20 
years of age. The single proband without episodes triggered by febrile illness (proband 18, 
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family 11) was diagnosed with ‘episodic migraine’ similar to the description by Potic et al 
(Potic et al 2015). Children were noted to have hearing impairment and visual dysfunction 
that were very slowly progressive (see Supplementary material).  In 3 cases, hearing 
impairment was diagnosed before or at the same age as the first neurological episode (cases 
3, 11 and 18) but in the other 15 cases, hearing impairment was diagnosed often years after 
the febrile episodes (1.5 – 11 years) and was not apparent immediately. Nine cases had clear 
nystagmus which often but not always persisted following improvement of the other 
symptoms. Interestingly, cases 1-7 demonstrated marked variability in their pure tone 
audiograms, showing occasional improvement.  
 
Audiological data are summarized in Table 2. Six  cases (cases  3, 4, 6, 16 ,17 ,18) had mild 
hearing loss, 8 had moderate (cases 1,2, 7, 9, 10 ,12 ,14 ,15) and 4 patients (cases 5, 8, 11, 13) 
had severe hearing loss. Hearing impairment tended to affect lower frequencies initially; it 
was progressive in 15 of the 18 cases (Table 2 and Fig. 3). In several cases, progression 
resulted in profound bilateral hearing loss. Some patients (cases 1, 2, 7 and 12) can only 
communicate with sign language (although this was not always the case) even though their 
pure tone audiogram shows a moderate to severe hearing loss.  Their mode of communication 
reflects the very poor ability to understand speech even in quiet environment. Four  patients 
(cases 9,11,15, 16) underwent cochlear implantation and some, particularly the children 
(cases 15 and 16), have gained significant benefit (See Supplementary Information, cases 15 
and 16).  
 
Hearing impairment was consistent with auditory neuropathy. Detailed audiological data are 
shown for case 17 in figure 4. Thirteen of the 15 patients tested, had OAEs; in two cases they 
were noted to be of particularly high amplitude (Fig. 4B, Fig. S2). The two cases (case 1 and 
case 13) without OAEs were aged 38 and 26 years and it is conceivable that OAEs had been 
present earlier but since disappeared as has been described for other types of auditory 
neuropathy. ABRs were markedly abnormal in all the 17 cases tested. Speech perception was 
often poor, especially in comparison with pure tone audiogram which showed only moderate 
or mild-moderate hearing loss in cases 15-18 (see Supplementary Information and 
Supplementary Figures 5 and 6). Fig.4 illustrates data for case 17, family 10 (Rosewich et al 
2014). Pure tone audiogram shows symmetric, mild to moderate hearing loss (Fig. 4A). The 
discrimination of monosyllabic words in quiet was clearly impaired for conversational sound 
intensities (at 65dB 50% correct discrimination at the right ear; and 60% at the left ear, but 
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near normal at higher sound levels (80dB: 95%/100% at right /left ear). The speech 
recognition threshold in 65dB background noise (Oldenburger Sentence test, binaural) was at 
a signal to noise ratio of +0.5dB (Brand and Wagener, 2017). Despite the hearing impairment 
86dB clicks readily elicited Transitory Evoked OAEs (TEOAE) (Figure 4B). Tone-evoked 
Distortion Product OAEs (DPOAEs) were present at higher amplitudes across all  
frequencies (Fig. 4D) indicating that the origin of the hearing impairment resides downstream 
of OHCs. We did not detect obvious ABRs  (Fig. 4C and Supplementary Figs S2, S3, S4, S5, 
S6). Transtympanic electrocochleography (Figure 4C), which enables direct recordings of 
cochlear potentials showed the presence of  cochlear microphonic potentials but much 
reduced (Fig. 4D). This indicates intact OHC function even in the low frequency apex of the 
cochlea, where the greatest hearing impairment is apparent in the pure tone audiogram.  
 
To address the distinct effects of Glu818Lys on the α3 containing Na/K-ATPase, we 
expressed it with E1 in Xenopus laevis oocytes. The 818 position is located at the cytoplasmic 
side of transmembrane helix 6 (Fig. 5A), where it forms a salt bridge with the backbone 
carbonyl of Arg930 (Fig. 5B), a residue known to stabilize the C-terminus (Morth et al. 2007; 
Poulsen et al. 2010). We therefore expected Glu818Lys to affect the C-terminal structure, 
which is critical for regulation of the Na+-specific third ion binding site in the pump (Poulsen 
et al. 2010, Yaragatupalli 2009, Vedovato 2010). If the pump is expressed and functional, it 
will produce a steady-state current since one net charge is exported during each catalytic 
cycle, and this current will be sensitive to the pump-specific inhibitor ouabain. With 
Glu818Lys, a ouabain-sensitive steady-state current is measured (data not shown). In the 
absence of extracellular K+, the pump will be restricted to binding and release of Na+ on the 
extracellular side (Fig. 1). Since the third Na+ is buried in the membrane, the membrane 
potential can shift the distribution of occluded (E1P) and open-to-the-outside (E2P) states, 
and the pre-steady-state currents from binding and release of the ion can be measured to 
determine this distribution (Holmgren et al 2000). We found that with Glu818Lys, the charge 
translocation is markedly left-shifted (V0.5 shifted from -72 mV to -202 mV), reflecting that 
the equilibrium is shifted between the sodium-binding E1P state and the open-to-the-outside 
E2P state towards E2P, i.e. Glu818Lys releases extracellular sodium more readily than the 
wild type pump (Fig. 6). The rate of sodium release is also accelerated compared to wild type 
α3 (Fig. 6), though to a lesser degree than when the C-terminal structure is directly perturbed 
by mutagenesis (Poulsen 2010). The CAPOS mutation also causes an inward current in the 
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absence of extracellular K+, which is not seen with the wild-type pump (Fig. 6A). The Na,K-
ATPase is known to carry an inward current of H+ under certain conditions, but usually not 
when high Na+ levels are present extracellularly (Li et al 2006). The pump contains a 
hemichannel towards the third ion binding site which is controlled by the C-terminus. 
Disturbing the C-terminal structure was previously reported to cause inward currents and 
accelerated Na+ release by opening of a hemichannel towards the third ion binding site 
(Poulsen 2010).  
 
To test if Glu818Lys does indeed cause opening of the C-terminal structure, we performed 
Molecular Dynamic (MD) simulations from the structure of a K+-occluded pump (Shinoda 
2009). In agreement with the electrophysiological data, we found that Glu818Lys causes an 
opening of the C-terminal pathway that allows rapid entry of water molecules towards the ion 
binding site (Fig7A), but also that the effect is less pronounced than for direct mutations of 
the C-terminus (Fig 7B).  Thus, the CAPOS mutation compromises pump function by 
destabilizing the Na+-occluded state.  
 
 
DISCUSSION 
 
The patients presented here share remarkably similar histories - sudden episodes of 
neurological decline and ataxia, precipitated by febrile illness, and followed by progressive 
visual and hearing loss. In most cases, hearing loss was not apparent immediately, but some 
considerable time, often years, after the febrile episodes. It is unknown whether hearing was 
reduced or worsened during febrile episodes as has been reported by patients with 
temperature-sensitive AN related to OTOF gene mutations. (Starr et al, 1998, Zhang et al, 
2016 ). Our cases, together with others presenting less well-reported features, such as 
seizures, athetosis, choreoathetosis, dystonia, autistic features and mild learning disabilities, 
suggest that the phenotype partially overlaps other ATP1A3-related disorders (RDP and 
AHC). However, optic atrophy and hearing impairment appear confined to the CAPOS 
mutation (Demos et al 2014; Rosewich et al 2014; Heimer et al 2015; Potic et al 2015; Maas 
et al 2016).  
We report 18 patients of whom 11 are females and 7 are males, and in all four cases with 
transmission to subsequent generations this occurred through a female (figure 2). However 
among the cases in the literature there are 11 females and 11 males (Demos et al 2014; 
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Rosewich et al 2014; Heimer et al 2015; Potic et al 2015; Maas et al 2016) and the 
transmission in familial cases was through females in 4 instances (Demos et al 2014;  Heimer 
et al 2015; Potic et al 2015) and through males in two cases (Demos et al 2014; Potic et al 
2015). The gender distribution and transmission to a second generation therefore seems to be 
without any particular pattern.  
 
The location of the residue Glu818Lys suggests that it impacts the C-terminal structure, and 
our electrophysiological characterization and molecular dynamics simulations confirm that it 
has effects similar to what was previously observed when mutating the C-terminus: very low 
affinity for extracellular sodium and a high rate of sodium release from the third ion binding 
site (Fig. 6). However, other mutations that affect the C-terminal structure, e.g. p.Asp992Tyr, 
cause AHC and not CAPOS. Furthermore, a substitution analogous to that in CAPOS, 
located very close by, p.Glu815Lys, is a hotspot for AHC (Pangiotakaki et al 2015; Viollet et 
al 2015). The p.Glu815Lys mutation causes a severe form of AHC with early onset, and 
biochemical studies suggest that it abolishes pump functionality (Weigand et al 2014 ). In 
CAPOS, it seems unlikely that pure loss-of-function would explain the deaf-blindness; the 
retinal and spiral ganglion neurons must be particularly affected by this one mutation. We 
therefore suspect that p.Glu818Lys confers a gain-of-function and/or an altered interaction 
with proteins specific to the ganglion neurons that future studies will be required to 
determine. However, the extended symptom pattern found in the 18 patients here, including 
the various movement disorders and psychological symptoms, which overlap with symptoms 
observed in RDP and AHC patients, could well be directly due to the observed impaired 
pumping, which will impact all D3 expressing neurons.  
 
We demonstrate that hearing impairment in patients with CAPOS is an auditory neuropathy 
and that the lesion lies downstream of OHC function. Indeed, the presence of OAEs in 13 of 
the 15 cases tested here suggests that OHC function is intact as corroborated by cochlear 
microphonic potentials in case 17, where electrocochleography was performed, and the 
observation that ABRs were pathological or absent in all CAPOS patients. In auditory 
neuropathy, synchronized activation of afferent SGNs by glutamate release at IHC ribbon 
synapses and/or propagation of spikes along the auditory pathway are impaired, resulting in 
poor or absent CAP and ABR and degraded speech perception and binaural hearing (Giraudet 
and Avan, 2012; Rance and Starr, 2015; Moser and Starr, 2016).  
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Therefore, patients with auditory neuropathy characteristically describe difficulty with 
hearing and understanding speech, especially in noisy environments (documented in CAPOS 
cases), difficulty localizing sound, and reduced music appreciation. Speech recognition and 
ABRs are typically more severely affected than would be expected on the basis of pure tone 
audiograms (see Fig. 3 and Fig. 4 and Supplementary Information Cases 15,16,17,18).  
 
The α3 subunit of the Na+/K+-ATPase encoded by the ATP1A3 gene, shows highest 
expression in neurons; in the auditory system, it is prominently expressed in SGNs in the 
inner ear of several rodent species (McGuirt and Schulte 1994; Erichsen et al 1996; McLean 
et al 2009), both in the cell bodies and afferent terminals of myelinated nerve fibers 
contacting IHCs and in unmyelinated medial efferent neurons contacting OHCs (McLean et 
al 2009 ). As these efferent fibers are responsible for suppression of OHC activity, the high 
levels of α3 may explain why OAEs in some patients with CAPOS were unusually large 
(Cases 3, 14 and 17; Fig. S1, S4 and 4B). 
 
Auditory neuropathy is important to diagnose because hearing rehabilitation differs from that 
of other types of sensorineural hearing impairment. Conventional hearing aids primarily 
amplify sound, and typically do not help auditory neuropathy subjects where the sound 
amplification by OHCs is intact (Rance and Starr 2015 ); in auditory neuropathy, it is the 
neural sound encoding and propagation of information which are impaired (Giraudet and 
Avan 2012). Instead, cochlear implantation, which directly stimulates the neural pathways, 
can successfully treat some forms of auditory neuropathy depending on the site of the lesion 
(Harrison et al 2015). For example, patients with disorders of IHCs, their synapses or the 
myelinated dendrites of SGNs (such as those due to missense mutations in OPA1) often 
benefit from cochlear implantation because the site of pathology can be bypassed by 
electrical stimulation (Santarelli et al 2015). In contrast, in disorders affecting distal 
myelinated dendrites, SGN cell bodies, or their central axons, the outcome of cochlear 
implantation is variable and many patients do not benefit (Rance and Starr 2015; Giraudet 
and Avan 2012). Interestingly, two of the four CAPOS patients with cochlear implants (the 
two youngest recipients, cases 15 and 16) have markedly benefitted as judged by improved 
speech recognition (see Supplementary Information). 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
12 
 
Clinically, auditory neuropathy is straightforward to diagnose if the history is suggestive, and 
if the correct tests are performed. Investigations may lead to the diagnosis of a known 
syndrome or non-syndromic auditory neuropathy, as in the case of OTOF mutations, which 
exert their effect at the IHC synapse, and which may be successfully helped by cochlear 
implantation (Rodriguez-Ballesteros et al 2003; Rouillon et al, 2006; Santarelli et al, 2015). 
In CAPOS patients, severe visual impairment due to progressive optic atrophy on top of the 
auditory neuropathy presents an additional challenge in establishing a satisfactory mode of 
communication, particularly in those who rely on vision for lip reading. For patient 
management and prognosis, auditory neuropathy is an important diagnosis to make. 
 
 
MATERIALS AND METHODS 
 
Electrophysiology 
Plasmids encoding human α3 and β1 subunits of Na+/K+-ATPase were purchased from 
Origene (Origene, Rockville, MD, USA) and subcloned into the pXOON vector using 
EcoRI and NotI (Jespersen et al 2002)). p.Glu818Lys was constructed with the quick change 
lightning site directed mutagenesis kit according to the manufacturer’s instructions (Agilent 
Technologies). Constructs were sequenced to verify successful mutagenesis. α3 contains 
mutations p.Gln116Arg and p.Asn127Asp to reduce ouabain resistance (Price and Lingrel 
1988 ). 
In preparation of mRNA transcription, the plasmids were linearized using NheI, purified 
using standard phenol/chloroform extraction, and mRNA was transcribed using the 
mMessage mMachine T7 Ultra Kit (Ambion, Life Technologies, Carlsbad, CA, USA) 
according to manufacturer’s instructions. 
Oocytes from Xenopus laevis were isolated and defolliculated. 50 nl of a mixture of α3 
(10 ng) and β1 (5 ng) mRNA was injected into Stage V and VI oocytes. Oocytes were 
incubated at 11 °C for 3–8 days prior to electrophysiological analysis. 
Measurements were performed with an OC-725C voltage-clamp apparatus (Warner 
Instruments Corp., Hamden, CT, USA) and a Digidata 1440A (Molecular Devices, 
Sunnyvale, CA, USA) using the two-electrode voltage-clamp technique using buffers with or 
without 10 mM ouabain and otherwise: 115 mM NaOH, 110 mM succinic acid, 10 mM 
Hepes, 5 mM BaCl2, 1 mM MgCl2, 0.5 mM CaCl2, 1 μM ouabain, pH 7.4. Measurements 
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were performed in 200 ms voltage jumps in steps of 20 mV. Data was recorded with pClamp 
10.4 (Molecular Devices) and analysed with Graph Pad Prism 7 (Graph Pad Software). 
Measurements in buffer containing 10 mM ouabain were subtracted from measurements 
without to yield Na+/ K+-ATPase specific pre-steady-state currents, which were fitted with 
single exponentials to determine charge translocation and rate constants were determined by 
fitting single exponentials. 
 
Molecular dynamics simulations 
All-atom MD simulations were performed using a similar protocol as in our previous studies 
of wild-type Na+/K+ -ATPase and its mutants in various conformational states (Kopec et al 
2014; Han et al 2017; Hilbers et al 2016). Here, the crystal structure of Na+/K+-ATPase from 
shark renal gland with bound MgF42- and K+ (PDB ID: 2ZXE, a stable analog of the 
E2*Pi*2K+ state was used as a starting point of the simulations (Shinoda et al 2009). The 
protein crystal structure, including bound potassium ions, was embedded in a fully hydrated 
1-palmitoyl,2-oleoyl-sn-glycero-3-posphocholine (POPC). The MgF42- molecule was 
manually deleted prior to the insertion. Glu818Lys (Glu828Lys in shark renal gland 
numbering) and other C-terminal point mutations (Arg940Pro and Arg1005Gln in shark renal 
gland numbering, and also YY-AA, where two final tyrosines of the α subunit were replaced 
by alanines) (Poulsen et al 2010) were introduced with Pymol (The PyMOL Molecular 
Graphics System, Version 1.7.4 Schrodinger, LLC).  
System construction – The K+ coordinating residues: Glu334, Glu786 and Asp815 were kept 
protonated, as previously reported (Yu et al 2011). Additionally, charged residues involved in 
binding of the third Na+ ion in E1 conformations of the pump, Asp933 and Glu961, were also 
protonated, as previously suggested (Poulsen et al 2010). The remaining glutamates and 
aspartates were kept in their charged forms. The Na+/K+-ATPase was embedded in an 
equilibrated POPC membrane (376 lipid molecules) and surrounded with ~63000 water 
molecules. Electroneutrality was achieved by adding an adequate number of K+ ions, 
randomly placed in the aqueous solution prior to simulations. 
 
Patients  
Details on the patients in this report were collated after the diagnosis of CAPOS was made; 
the genetic studies were based on clinical suspicion (apart from case 18), typically after 
several years’ search for a diagnosis. Clinical and audiological data have been collected 
retrospectively (for details see Tables 1 and 2 and Supplementary Material) except for data 
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from case 17 at age 14 which was acquired in the process of preparing the manuscript. 
Details are outlined in Supplementary Material. 
Briefly, families 1 and 2 are unrelated and of Swedish origin; families 3, 4 and 5 are 
unrelated and of Danish origin; family 6 is French; families 7, 8 and 9 are from the UK, one 
of South Asian origin, the other two, British Caucasian; family 10 is German (reported 
previously but without detailed audiological data (Rosewich et al, 2014) and in family 11 the 
affected child has Spanish and Italian parents. Families 1, 2, 3, and 4 are two generation 
families (Fig. 2); the remainder are simplex. The patients ranged from 8 to 59 years at 
diagnosis.  
 
Audiological examinations 
 OAE in case 17 (Figure 4) was performed using ILOv6, Otodynamics according to 
manufacturer’s instructions. The rejection level was 49.5 dB SPL. DPOAE stimuli 
were 65/55 dB and the frequency ratio was 1.22. 
Calculation of Pure Tone Averages (PTA0,5,1,2,4 kHz) and classification of the degree of 
hearing impairment followed the European recommendations  (Mazzoli M et al, 2003), where 
20-40 dB HL is mild; 41-70 dB Hl is moderate; 71-95 dB HL is severe; and >95 dB Hl is 
profound hearing impairment 
 
Cochlear Microphonic 
Identification of cochlear microphonic potentials was achieved in cases 3, 7, 9, 11, 12, 15, 16 
and 17. In case 17 this was by electrocochleography. In the other cases, the cochlear 
microphonic was identified using a click ABR following recommended practice 
(http://www.thebsa.org.uk/wp-content/uploads/2015/02/CM).  
  
Electrocochleography 
Transtympanic electrocochleography was performed for case 17, using the Navigator pro 
system under sedation. The examination was done in the room adjacent to the MRI scanner 
(no electric or sound shielding) where other clinical data have been obtained in the same 
sedation which was necessary in order to avoid involuntary movements. A disposable 
monopolar needle electrode (902-DMG75-TP, Natus) was placed on the promontory and 
sound applied at a rate of 9.8 Hz via a custom-built 1m long plastic tube from a TDH39 
loudspeaker/P210 amplifier to avoid electric artifacts from the sound system  to superimpose 
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onto cochlear microphonic potentials based on a sound delay of 3 ms.  Filters settings 
were:high pass 10Hz, low pass 5000 Hz, 50 Hz notch filter. Electrocochleography was 
performed in case 12 with Interacoustics Eclipse EP equipment under general anaesthesia 
using insert earphones, stimuli/sec 11,3, low pass 3000 Hz, high pass none, polarity: 
alternating. The recording room was an ordinary hospital room e.g. not a Faraday’s cage or 
an audiometric booth. 
Speech tests 
Case 7 underwent Dantale I speech perception test (Elberling et al, 1989). Resukts are shown 
in Supplementary Material. 
Case 17 underwent Oldenburger sentence test (Brand and Wagener, 2017). 
Case 18 underwent  The Goettinger Speech Test (Chilla et al, 1976), which measures speech 
understanding in children between 3 to 4 and 5 to 6 years of age. This test utilises a list of 
words or picture cards that must be repeated and matched to the correct word.  This test is not 
performed in noise.  
Case 18 also underwent a test for language skills called TROG-D (test zur Überprüfe des 
Grammatikverständnisses) (Kampfhaus RW, 2005), which is a German adapted test assessing 
grammatical comprehension in children aged 3-10. The test measures  the understanding of 
18 different sentence constructions; each sentence construction is presented four times each 
using different test stimuli. 
 
Ophthalmological examination 
Electrophysiological examinations were performed in accordance with principles of the 
International Society for Clinical Electrophysiology of Vision (Odom et al 2016; Odom et al 
2010 ). Optical coherence tomography (OCT) scanning to measure retinal nerve fiber 
thickness profile (RNFL) was performed using the Heidelberg Spectralis version 1.7.0.0 
(Heidelberg Engineering, Heidelberg, Germany) using the inbuilt software for scanning the 
optic nerve head. 
 
Sanger Sequencing 
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ATP1A3 was sequenced by bi-directional Sanger sequencing using standard methods. Primer 
sequences are available on request. 
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Figure legends 
 
 
Fig. 1. Schematic of the catalytic cycle of the Na,K-ATPase. The forward reaction of the pump is 
clock-wise. The membrane is indicated by horizontal lines with the extracellular compartment 
denoted ‘ex’ and the cytoplasm denoted ‘in’.  In the so-called E1 state, the enzyme has high affinity 
for sodium, and in the E2 state it has high affinity for potassium. During the cycle, the enzyme acts 
as both substrate, kinase and phosphatase, and the phosphorylated states of the pump are denoted 
with a P (E1P and E2P). Starting in the top left corner, the pump has three Na+ (blue spheres) 
occluded in the E1P state that are released extracellularly when the pump opens to the outside in the 
E2P state. The open pump will bind two K+ (red spheres) and dephosporylate to the E2 state where 
the K+ are occluded . Opening of the pump on the intracellular side and transition to the E1 state 
allows release of K+ and binding of Na+. With phosphorylation of the pump, the Na+ are then 
occluded in the E1P state. The P in the E1P and E2P states signifies that the pump is 
phosphorylated by the ATP that provides the energy for the transport. A full circle depends on 
intracellular Na+ and ATP and extracellular K+. The grey square indicates that in the absence of 
extracellular K+ and intracellular ADP, the pump is restricted to transitions between E1P and E2P, 
i.e. extracellular release and binding of Na+.  
 
Fig. 2. Pedigrees of four of the families investigated in the study (a-d). All the families (families 
1,2,3,4) show segregation of the ATP1A3 mutation c.2452G>A;p.Glu818Lys with the disease. 
Probands are indicated by arrows. The ATP1A3 molecular result is indicated below each individual 
who provided DNA. N = normal allele. Vertical line through a symbol means age -related hearing 
impairment. A diagonal line through an individual indicates that the person is deceased and a 
double-line between two parents indicates consanguinity. 
 
Fig. 3. Audiograms from cases 1, 5, 6, and 7 . Case 1 shows progressive hearing loss in the right 
ear. Cases 5, 6, and 7  demonstrate that low frequencies are predominantly affected and that the 
hearing loss is symmetrical.  
 
Fig. 4. Clinical data from case 17. A, Audiograms at 12 years (pink/light blue) and 14 years 
(red/blue) of age. B, TEOAE and DPOAE with high amplitudes. C, ABR to rarefaction (upper 
traces) and alternating (lower traces) click stimuli are absent (example left ear). A normal ABR is 
shown below in red with expected waveforms indicated. D, recording technique for transtympanic 
electrocochleography (ECochG): a needle is placed on the promontory, the bone covering the 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
25 
 
cochlea. The reference electrode (not shown) is on the contralateral mastoid. Sound stimuli are 
administered via a loudspeaker. E, summating potential/compound action potential complexes 
(arrows) to click stimulation in the patient (left ear; blue) have a very low amplitude, but the peak 
latency is comparable to that of a normal-hearing proband (representative example in red, bottom). 
Right: In response to 500 Hz tone burst stimulation, cochlear microphonic potentials were present. 
Black lines in E indicate the time of stimulus onset. Data were acquired at age 14.   
Note the scale bar difference between the patient data and the example of normal ECochG 
recording and the difference in the shape of the click response. 
 
Fig. 5. Structural context of p.Glu818. A, The tripartite pump is shown with the D subunit in grey, 
the E subunit in blue, and the J subunit in green. The membrane is indicated with horizontal lines, 
the cytoplasm is below. The two occluded potassium ions are visible as red spheres in the middle of 
the membrane. P.Glu818 (yellow sticks) is in the transmembrane part of the pump on the 
cytoplasmic side, close to the C-terminus (magenta sticks). B, A close-up of the structure around 
p.Glu818, viewed from the cytoplasmic side. The p.Glu818 carboxyl is less than 3Å from the 
backbone amide of Arg930, which coordinates the C-terminus. Figures made with Pymol using pdb 
2ZXE.  
 
Fig. 6. The CAPOS mutation affects the E1P-E2P equilibrium. A, The ouabain-sensitive pre-
steady-state currents of wild-type and p.Glu818Lys human Na+/K+-ATPase D3, co-expressed with 
E1 in Xenopus laevis oocytes, shows binding and release of extracellular sodium. B, Fitting of 
single exponentials to pre-steady-state currents as shown in C allows the charge Q moved to be 
determined (top). The midpoint potential V50 for the wild-type is -72 mV +/- 39 mV, and for 
Glu818Lys it is -202 mV +/- 40 mV. The rates (bottom) are also determined from the pre-steady-
state currents, and the rates for the mutant are higher than for the wild-type.  
 
Fig. 7. MD simulations of the effect of the CAPOS mutation on the C-terminal structure. A,  
The degree of hydration of  residue  p.Asp933 at the third binding site is evaluated. The radial 
distribution functions g(r) between p.Asp933 and water molecules shows a peak for r < 5Å if the 
residue is hydrated. No peak is observed for the wild-type, but a clear peak is seen for p.Glu818Lys. 
Similarly, other mutations affecting the structure terminus (p.Arg940Pro, p.Arg1005Gln and YY-
AA) also cause hydration of p.Asp933. B, The radius of the bottleneck of the pathway was 
determined. In the wild-type, the radius is narrow, and the channel is closed, while p.Glu818Lys 
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causes an opening of the channel. Other mutations directly affecting the C-terminus cause even 
larger openings.  
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Legends for Supplementary figures S1-S7 
Fig. S1. Representative sequence chromatograms for the ATP1A3 missense mutation c.2452G>A; 
p.Glu818Lys compared to a normal control. The arrow indicates the nucleotide change of the 
heterozygous missense mutation. Nomenclature of mutation refers to the ATP1A3 RefSeq 
NM_152296.4, (Gene ID: NG_008015.1) with nucleotide number +1 being A of the start codon 
ATG. 
 
Fig. S2. A, Preserved OAEs at age 13 in case 3, with noticeable high amplitudes. B, ABR 
(calibrated in dB peSPL) from left and right ear in case 3 without reproducible responses  
 
Fig. S3. Case 12 at age 19 years. A Air conduction thresholds for right (red symbols) and left (blue 
symbols) ear. B. ABR with click stimulus in rarefaction and condensation mode, right and left ear. 
Phase-reversed cochlear microphonics at 80 dB nHL and higher intensities in combination with no 
stimulus artefact. C. Transtympanic electrocochleography with alternating click (right ear). A large 
summation potential is seen with threshold at 50 dB nHL pointing to preserved inner hair cell 
function. 
 
Fig. S4. Case 14  
A, Pure tone audiograms at age 29 years (pale lines) and at 32 years (dark lines) showing some 
progression in the right ear (red) and possibly in the left ear (blue). B, TEOAE and DPOAE are 
present in both ears. TEOAE Stimulus 83.7 and 85.8 dBpe, reject level = 48.0dBspl; DPOAE  
Stimulus = 70/70 dB; 8 pts/octave; F2/F1 – 1.22; reject level = 49.5 dBspl, Otodyamics Ltd ILOv6 
C, Click ABR shows no repeatable response at 100 dB nHL in either ear.  
 
Fig. S5. Case 15  
A, Pure tone audiogram at age 11 years showing moderate hearing loss.  B, TEOAE and DPOAE 
are present. TEOAE Stimulus 85.8 and 86.9 dBpe, reject level = 49.5 dBspl; DPOAE, Stimulus = 
65/55 dB; 3 pts/octave; F2/F1 – 1.22; reject level = 49.5 dBspl, Otodyamics Ltd ILOv6 C, Tone pip 
ABR shows no repeatable response at 80dBnHL at 4kHz. D, Click ABR showing cochlear 
microphonics are present in both ears, more marked on the right. Note that primary low frequencies 
are affected. 
 
Fig. S6. Case 16 
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A, Pure tone audiograms at age 8 years (pale lines) and 9 years (dark lines) showing severe low and 
high frequency hearing impairment on the right and profound low and moderate hearing loss on the 
left ear. There has been progression at 500 Hz in the left ear. B, TEOAE and DPOAE are present in 
both ears at age 7 years. TEOAE Stimulus 83.7 and 83.7 dBpe, reject level = 54.0 and 50.9 dBspl; 
DPOAE Stimulus = 65/55 dB; 3 pts/octave; F2/F1 – 1.22; reject level = 49.5 dBspl, Otodyamics 
Ltd ILOv6 C, Click ABR shows no repeatable response at 90dB nHL in either ear. D, Click ABR 
shows cochlear microphonics are present in both ears. 
 
Fig. S7. Optical Coherence Tomography (OCT) measuring the retinal nerve fiber thickness profile 
(RNFL) from case13. A) Retinal nerve fiber (RNFL) thickness profile (black curve) in case 13 at 
age 13 years shows a reduced RNFL thickness in all quadrants, temporal (TMP), superior (SUP), 
inferior (INF) and nasal (NAS) sides, in both eyes. OD, right eye; OS, left eye. The green area 
defines the 5th to 95th (normal thickness), the yellow area the 1st to 5th (border-line thickness) and 
the red area below the first percentiles (abnormal thickness). Color scale of the thickness profile is 
indicated in the color bar at the bottom of the figure.  
On the right, RNFL thickness in individual sectors and clock hours demonstrates decreased RNFL 
thickness in the superior (S), inferior (I), nasal (N) and temporal (T) quadrants of right and left eyes. 
RNFL measurements in corresponding quadrants is noted in μm. The table represents key 
parameters of optic nerve head and RNFL analysis. There is severe decreased average RNFL 
thickness with an average RNFL thickness of 45.22μm in the right eye and 47.22μm in the left eye. 
B) Eye fundus picture of affected case13 shows pale, almost white optic nerve of the left eye at age 
26 years. In unaffected people the optic nerve appears pink. 
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Y
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Y
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Y
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Y
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o at 5y 
Y
es at 22m
 
Y
es at 34m
 
V
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O
.U
 
1.0 
age 
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m
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otherw
ise 
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al at 7y &
 11y 
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0.3 at 34m
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O
C
T 
N
I 
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I 
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EP 
A
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bnorm
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Hearing Loss 
Y
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 Y
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Y
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Y
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es 
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Cerebellar ataxia 
Y
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Y
es at 3y 
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 N
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 N
europathy 
A
xonal neuropathy 
A
xonal neuropathy 
N
C
V
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al at 13y 
EM
G
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V
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5y norm
al 
N
o 
N
I 
C
T/M
R
I scan 
C
T and M
R
I: 
norm
al at 23y 
C
T norm
al at 24m
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M
R
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al at 16y 
C
T norm
al; M
R
I 
thin brainstem
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w
ide 4th ventricles 
at 13y 
 M
R
I norm
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T norm
al at 16y 
M
R
I at 13y: 
narrow
 cerebellar 
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 Subject 
Case 7  
Case 8 
Case 9  
Case 10  
Case 11  
Case 12  
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N
I 
Y
es at 20m
 
N
I 
N
I 
Y
es at 3y 
Optic atrophy 
Y
es at 16y 
Y
es at 43y 
Y
es at 4y 
Y
es at 13y; 
confirm
ed 25y 
Y
es from
 at 30y 
Y
es at 8y; 
confirm
ed at 21y 
V
isual acuity 
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 Y
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N
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w
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N
o 
N
o 
N
o 
N
o 
N
europathy 
N
I 
EN
G
 
and 
N
C
V
 
norm
al at 38y 
N
I 
N
I 
N
I 
N
I 
C
T/M
R
I scan 
C
T: norm
al at 5y 
M
R
I 
(33y):A
trophic 
cochlear nerve 
w
ithout IA
C
 
hypoplasia 
N
I 
C
T norm
al at 20m
, 
M
R
I norm
al at 15y 
M
R
I norm
al at 24y 
C
T norm
al at 43y; 
M
R
I norm
al at 42y 
M
R
I norm
al at 3y; 
at 6y central and 
cortical atrophy, 
norm
al basal 
ganglia; norm
al 
spectroscopy; C
T 
tem
poral bone 
norm
al at 18y; 
M
R
I at age 19 y 
norm
al 
 
  
 
 Cases 13-18 
 
Subject 
Case 13  
C
ase 14  
C
ase 15  
C
ase 16  
C
ase 17  
C
ase 18 
Fam
ily 
fam
ily 6  
fam
ily 7  
fam
ily 8  
fam
ily 9  
fam
ily 10* 
fam
ily 11 
N
ationality 
French 
B
ritish 
B
ritish 
B
ritish A
sian 
G
erm
an 
Spanish/  Italian 
Sex and C
urrent age 
(2016) 
m
ale 30y 
m
ale 35y 
fem
ale 13y 
fem
ale 18y 
m
ale 13y 
m
ale 8y 
A
ge 
of 
onset 
of 
neurological 
dysfunction 
14m
 
22m
 
18m
 
18m
  
20m
 
O
nly 
auditory 
neuropathy 6y** 
N
um
ber of episodes 
2 
2 
3 
4 
M
ultiple 
M
ultiple 
Febrile trigger 
Y
es 
Y
es 
Y
es 
Y
es 
Y
es 
N
o; 
from
 
age 
2 
attacks of reduced 
physical 
activity, 
and confinem
ent to 
bed  
A
ge at last episode 
20y 
9y 
10y 
10y 
6y 
N
A
 
A
bnorm
al eye 
m
ovem
ents 
N
o 
Y
es, pendular 
nystagm
us 
N
o 
Y
es, interm
ittent 
nystagm
us 
N
I 
N
o 
Seizures 
N
I 
N
o 
N
o 
N
o 
N
o 
N
o 
Optic atrophy 
Y
es at 4y 
Y
es 
Y
es m
ild at 12y 
Y
es 
Y
es at 12 y 
N
o 
V
isual acuity 
V
A
 decreased at 
14y; V
A
:0.1 at 
20y; norm
al color 
vision &
 ER
G
 
20y  
R
educed from
 20y 
0.22/0.16 at 12y; 
ER
G
 norm
al age 
10y 
0.7/0.8 at 11y 
0.94/1.02 at 13y 
0.3 at 12y 
N
I 
O
C
T 
Thinned retinal 
nerve fiber layer 
at 26y 
N
I 
Thinning of nerve 
fibre layer at 10y 
 N
I? 
N
I 
N
I 
V
EP 
A
bnorm
al 
A
bnorm
al at 32y 
A
bnorm
al at 10y 
A
bnorm
al at 
7y,10y 
A
bnorm
al at 12y 
N
I 
Hearing Loss 
Y
es at 4y; 
fluctuating, 
progressive 
Y
es, m
oderate  to 
severe (upsloping); 
Y
es; low
 
frequency. 
Progressive 
Y
es at 5y, low
 and 
m
id-frequency 
progressive 
Y
es at 11y 
Y
es, at 6y, low
 
frequency 
 m
oderate to severe 
(flat) on R 
norm
al to 
profound in 5y 
A
uditory 
N
europathy 
Y
es 
Y
es 
Y
es 
Y
es at 5y 
Y
es 
Y
es 
Cerebellar ataxia 
Y
es at 14 m
 
Y
es 
Y
es, very m
ild 
Y
es 
Y
es 
U
nsteady gait and 
clum
sy 
Areflexia 
N
I 
Y
es 
Y
es 
Y
es 
Y
es 
N
o 
Pes cavus 
N
I 
N
o 
N
o 
N
o initially, but has 
high arches 
N
o 
N
o 
D
ystonia 
N
I 
N
o 
N
o 
N
o, choreiform
 at 
tim
es; titubation  
Y
es, m
ild 
N
I 
A
utistic features 
N
o 
N
o 
W
ithdraw
n 
B
ehaviour 
problem
s initially 
N
o 
N
o 
N
europathy 
N
I 
N
I 
N
orm
al EM
G
 and 
N
C
V
 at 9y 
N
orm
al N
C
V
 at 3y, 
8y, 11y 
H
ypotonia, 
dysarthria 
N
I 
C
T/M
R
I scan 
M
R
I 
norm
al 
at 
15y 
M
R
I norm
al at 22y 
M
R
I 
norm
al 
at 
10y 
M
R
I norm
al at 2y, 
3y, 7y, 11y 
M
R
I norm
al at 12y; 
Proton 
M
R
S 
norm
al lactate 
M
R
I norm
al at 6y 
 
Legend for Table 1 
Sum
m
ary of clinical features.** see Supplem
entary inform
ation for details 
C
V
I = central visual im
pairm
ent (cause of visual problem
s are of central nervous origin); ER
G
 = electroretinogram
; IA
C
 = internal auditory canal; 
L = left; m
 = m
onths; N
A
 = not applicable; N
I = no inform
ation; O
.D
 = oculus dexter (right); O
.S = oculus sinister (left); O
.U
 = oculi utrisque 
(both eyes); R
 = right; V
A
 = visual acuity;  y = years  
* (R
osew
ich H
 et al, 2014) 
 Table 2. Detailed Audiological features 
Patient 
ABRs/ 
PTA
0.5-4 
kHz R/L dB 
(age)* 
OAEs 
Speech 
recognition 
Diagnosis 
of HI (age) 
Diagnosis 
of CAPOS 
Cochlear 
micro-
phonics 
Vestibular 
dysfunction 
Progression 
of HI 
Treatment 
case 1 fam
ily 1 
A
bnorm
al 
64/74(7y) 
A
bsent (at 
38y) 
N
I 
7y 
 51y 
N
I 
Y
es (38y) 
Y
es 
M
oderate→
 
severe 
H
A
 
case 2 fam
ily 1 
A
bnorm
al 
63/69 
(14y) 
Present 
(9y) 
N
I 
5y 
 30y 
N
I 
Y
es (16y) 
 N
I 
M
oderate 
H
A
 
case 3 fam
ily 1 
A
bnorm
al 
40/34 (5y) 
Present 
(13y)- 
high 
am
plitude 
N
I 
 4y-low
 
frequencies 
 26y 
Y
es 
N
I 
Y
es 
M
ild 
H
A 
case 4 fam
ily 1 
A
bnorm
al 
38/29 
(11y) 
Present 
(10y) 
N
I 
11y-low
 
frequencies  
 16y 
N
I 
N
I 
N
o 
M
ild 
H
A
 10y 
case 5 fam
ily 2 
A
bnorm
al 
86/93 (4y) 
N
I  
Poor 
30m
-low
 
frequencies 
 50y 
N
I 
Severe  7y 
Y
es 
Severe→
 
profound 
H
A
 
case 6 fam
ily 2 
A
bnorm
al 
46/31 
(10y) 
Present 
(10y) 
N
I  
3y 
 29y 
N
I 
W
eak caloric 
response at 
10y 
Y
es 
M
ild→
 
Severe 
H
A
 
case 7 fam
ily 3 
A
bnorm
al 
55/65 
(25y) 
Present 
Poor* 
5y 
 32y 
 Y
es 
N
I 
Y
es 
M
oderate 
H
A
* 
case 8 fam
ily 3 
A
bnorm
al 
75/79 
(25y) 
N
I  
Poor 
4y 
 59y 
N
I 
N
I 
Y
es 
Severe→
 
Profound 
H
A 
case 9 fam
ily 4 
A
bnorm
al 
56/57 
(17y) 
Pass/refer 
(18y) 
Poor 
 form
al 
testing not 
done 
3.5y 
 22y 
Y
es 
N
I 
Y
es 
M
oderate 
H
A
; C
I 19y 
Table 
C
lick here to dow
nload Table C
A
P
O
S
V
10-Table 2-H
G
-acc corr-031117.docx 
 case 10 fam
ily 
4 
A
bnorm
al 
45/58 
(21y) 
Present 
(25y) 
Poor 
 form
al 
testing not 
done 
 
10y 
 25y 
N
I 
N
I 
Y
es 
M
oderate 
H
A
 10y 
case 11 fam
ily 
4 
A
bnorm
al 
95/99 
(33y) 
N
I 
Poor 
4y 
 46y 
Y
es 
N
I 
Y
es 
Severe 
H
A
 4y;C
I  
43y 
case 12 fam
ily 
5 
A
bnorm
al 
53/56 
(18y) 
Present 
(19y) 
Poor 
 form
al 
testing not 
done 
12y 
 21y 
Y
es 
N
I 
Y
es 
M
oderate 
H
A
 6y; C
I 
considered* 
case 13 fam
ily 
6 
A
bnorm
al 
88/93 
(26y) 
A
bsent at 
26y 
Poor 
10y 
 29y 
N
I 
Y
es at 26y 
Y
es 
Severe 
 H
A
 6y 
case 14 fam
ily 
7 
A
bnorm
al 
54/49 
(29y) 
H
igh 
am
plitude 
Poor 
hearing in 
noise 
10y 
 34y 
N
I 
N
I 
Y
es 
M
oderate→
 
M
oderate/ 
severe 
H
A 
case 15 fam
ily 
8 
A
bnorm
al 
53/48 
(12y) 
Present 
Poor 
5y 
 12y 
Y
es 
N
o, 10y 
Y
es 
M
oderate 
H
A
 5y; C
I 
12y 
case 16 fam
ily 
9 
A
bnorm
al 
34/34 (8y) 
 
Present* 
Poor 
5y 
 17y 
Y
es 
Y
es 
Y
es 
M
ild→
m
ild/
m
oderate 
H
A
; C
I 
10y, 16y 
case 17 fam
ily 
10 
A
bnorm
al 
 27/29 
(12y) 
 
H
igh 
am
plitude 
Poor 
hearing in 
noise  
11y 
 12y 
Y
es 
N
I 
yes 
M
ild  
/m
oderate 
- 
case 18 fam
ily 
11 
N
I 
 24/18 
(6,6y) 
Present 
(6y) 
Poor 
6y-low
 
frequencies 
8y 
N
I 
N
I 
N
o 
M
ild 
H
A
 
 N
I = no inform
ation 
H
A
 = H
earing A
id 
C
I= cochlear im
plant ; *see Supplem
entary m
aterial. PTA
0.5-4 kH
z R
/L dB
 m
eans averaged PTA
 in dB
 H
L of right-R
, and left-L ear, respectively. 
classification of degree of hearing im
pairm
ent according to M
azzoli M
 et al (2003) 
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